MAP2K1 and central nervous system cancer: Recently, miR-181b-5p was found to inhibit glioma cell proliferation, migration, invasion and tumorigenesis by targeting IGF-1R[8] and to reduce chemoresistance to temozolomide in glioma cells by targeting MEK1[9].